2018300-62-2 Usage
Uses
Used in Pharmaceutical Industry:
(S)-7-(3,5-dimethoxyphenyl)-N-(1-methylpiperidin-3-yl)-4-propionyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-carboxamide is used as a potential psychotropic agent for the treatment of various mental health conditions. Its complex molecular structure and potential therapeutic effects make it a promising candidate for further research and development in the field of medicinal chemistry.
Used in Drug Development:
(S)-7-(3,5-dimethoxyphenyl)-N-(1-methylpiperidin-3-yl)-4-propionyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-carboxamide is also used in the development of new drugs targeting mental health disorders. Its unique molecular structure and potential psychotropic properties allow researchers to explore its efficacy and safety in treating different mental health conditions, contributing to the advancement of drug development in this area.
Check Digit Verification of cas no
The CAS Registry Mumber 2018300-62-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,0,1,8,3,0 and 0 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 2018300-62:
(9*2)+(8*0)+(7*1)+(6*8)+(5*3)+(4*0)+(3*0)+(2*6)+(1*2)=102
102 % 10 = 2
So 2018300-62-2 is a valid CAS Registry Number.
2018300-62-2Relevant academic research and scientific papers
Popp, Tobias A.,Tallant, Cynthia,Rogers, Catherine,Fedorov, Oleg,Brennan, Paul E.,Müller, Susanne,Knapp, Stefan,Bracher, Franz
, p. 8889 - 8912 (2016)
CBP (CREB (cAMP responsive element binding protein) binding protein (CREBBP)) and P300 (adenovirus E1A-associated 300 kDa protein) are two closely related histone acetyltransferases (HATs) that play a key role in the regulation of gene transcription. Both proteins contain a bromodomain flanking the HAT catalytic domain that is important for the targeting of CBP/P300 to chromatin and which offeres an opportunity for the development of protein-protein interaction inhibitors. Here we present the development of CBP/P300 bromodomain inhibitors with 2,3,4,5-tetrahydro-1,4-benzoxazepine backbone, an N-acetyl-lysine mimetic scaffold that led to the recent development of the chemical probe I-CBP112. We present comprehensive SAR of this inhibitor class as well as demonstration of cellular on target activity of the most potent and selective inhibitor TPOP146, which showed 134 nM affinity for CBP with excellent selectivity over other bromodomains.
